Title: Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for Helicobacter
pylori infection in Hainan: A single-center, open-label, noninferiority, randomized controlled
trial
Version: 3 Date: 31 May 2023
Reviewer's report:
General:
In this report, the authors investigated the efficacy, adverse events, patient compliance, and costs
of high-dose dual therapy with eprazole-amoxicillin and the conventional quadruple therapy for
H. pylori infection in Chinese patients. Authors concluded that high-dose eprazole-amoxicillin
dual therapy is equally effective, more than 90%, and safer and less costly than bismuth-
containing quadruple therapy.
This guideline was well written and may have potential.
Minor comments:
1. Authors should mention acid inhibitory effect of eprazole in Introduction section.
2. This trial was used 14-days treatment. How about 7-days treatment?
3. The study ultimately included 200 patients with chronic gastritis who tested positive for H.
pylori. How about sample power?
4. In general, dosing times is important for compliance. However, tid regimen (Group A) is
better than bid regimen (Group B). Why?
5. Result: Goup A # Group A
6. Please delete Age Distribution.
7. Authors should add a Table that show a risk for successful eradication by multivariate analysis.
8. No culture data to antimicrobial agents is serious problem. At first, authors announce that it
is important alternative treatment is important due to increase of resistant strain of antimicrobial
agents.
9. Compared with previous reports in Chinese, efficacy of bismuth-containing quadruple therapy
is too high.
Title: Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for Helicobacter
pylori infection in Hainan: A single-center, open-label, noninferiority, randomized controlled
trial
Version: 3 Date: 31 May 2023
Reviewer's report:
General:
In this report, the authors investigated the efficacy, adverse events, patient compliance, and costs
of high-dose dual therapy with eprazole-amoxicillin and the conventional quadruple therapy for
H. pylori infection in Chinese patients. Authors concluded that high-dose eprazole-amoxicillin
dual therapy is equally effective, more than 90%, and safer and less costly than bismuth-
containing quadruple therapy.
This guideline was well written and may have potential.
Minor comments:
1. Authors should mention acid inhibitory effect of eprazole in Introduction section.
2. This trial was used 14-days treatment. How about 7-days treatment?
3. The study ultimately included 200 patients with chronic gastritis who tested positive for H.
pylori. How about sample power?
4. In general, dosing times is important for compliance. However, tid regimen (Group A) is
better than bid regimen (Group B). Why?
5. Result: Goup A # Group A
6. Please delete Age Distribution.
7. Authors should add a Table that show a risk for successful eradication by multivariate analysis.
8. No culture data to antimicrobial agents is serious problem. At first, authors announce that it
is important alternative treatment is important due to increase of resistant strain of antimicrobial
agents.
9. Compared with previous reports in Chinese, efficacy of bismuth-containing quadruple therapy
is too high.
Please review this paper.
user
Title: Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for Helicobacter
pylori infection in Hainan: A single-center, open-label, noninferiority, randomized controlled
trial
Version: 3 Date: 31 May 2023
Reviewer's report:
General:
In this report, the authors investigated the efficacy, adverse events, patient compliance, and costs
of high-dose dual therapy with eprazole-amoxicillin and the conventional quadruple therapy for
H. pylori infection in Chinese patients. Authors concluded that high-dose eprazole-amoxicillin
dual therapy is equally effective, more than 90%, and safer and less costly than bismuth-
containing quadruple therapy.
This guideline was well written and may have potential.
Minor comments:
1. Authors should mention acid inhibitory effect of eprazole in Introduction section.
2. This trial was used 14-days treatment. How about 7-days treatment?
3. The study ultimately included 200 patients with chronic gastritis who tested positive for H.
pylori. How about sample power?
4. In general, dosing times is important for compliance. However, tid regimen (Group A) is
better than bid regimen (Group B). Why?
5. Result: Goup A # Group A
6. Please delete Age Distribution.
7. Authors should add a Table that show a risk for successful eradication by multivariate analysis.
8. No culture data to antimicrobial agents is serious problem. At first, authors announce that it
is important alternative treatment is important due to increase of resistant strain of antimicrobial
agents.
9. Compared with previous reports in Chinese, efficacy of bismuth-containing quadruple therapy
is too high.
assistant